Comparative Pharmacology
Head-to-head clinical analysis: ALDORIL D30 versus HYDRO SERP 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALDORIL D30 versus HYDRO SERP 25.
ALDORIL D30 vs HYDRO-SERP "25"
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aldoril D30 is a combination of methyldopa, a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow, and hydrochlorothiazide, a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, decreasing plasma volume and peripheral resistance.
Hydrochlorothiazide inhibits the Na+/Cl- symporter in the distal convoluted tubule of the kidney, reducing sodium and chloride reabsorption and promoting diuresis. Reserpine depletes catecholamines in postganglionic sympathetic nerve endings by inhibiting the vesicular monoamine transporter, leading to reduced sympathetic outflow and vasodilation.
Oral: 1 tablet (hydrochlorothiazide 30 mg / methyldopa 500 mg) twice daily; maximum dose: 2 tablets twice daily.
Hydrochlorothiazide 25 mg orally once daily in the morning. Maximum 100 mg/day.
None Documented
None Documented
Terminal elimination half-life of hydrochlorothiazide is 6-15 hours; methyldopa half-life is 1.8 hours (normal renal function). In renal impairment, half-life of both components is prolonged.
Reserpine: terminal elimination half-life 33-45 hours (range 30-60 hours), with clinical context of prolonged autonomic effects lasting days; hydrochlorothiazide: terminal half-life 6-15 hours (mean 10 hours).
Renal: approximately 50% as parent drug and metabolites; biliary/fecal: minimal, less than 5%.
Renal (approximately 30-50% as unchanged drug and metabolites), biliary/fecal (approximately 50-70% as metabolites, with enterohepatic recirculation noted for reserpine component).
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination